2018吉非替尼联合艾迪注射液治疗晚期非小细胞肺癌的临床观察

602943

　　【摘要】目的：评价吉非替尼联合艾迪注射液治疗晚期非小细胞肺癌的近期疗效和不良反应。 方法：将44例患者随机分为两组，每组22例患者。治疗组给予艾迪注射液联合吉非替尼治疗。吉非替尼给予250?J每天口服一次，艾迪注射液给予50ml每天一次静脉输入。对照组仅予吉非替尼250?J每天口服一次治疗。结果：全部44例患者可评价疗效，治疗组和对照组有效率为40.9%和27.3%。疾病控制率分别为86.4%和59.1%。治疗组在疗效和疾病控制率均高于对照组，其中两组疾病控制率相比较具有统计学意义（P＜0.05)。常见不良反应多为I～Ⅱ度皮疹改变和腹泻,但通常可能耐受。结论：吉非替尼联合艾迪注射液治疗晚期非小细胞肺癌，可以提高疗效及降低治疗的相关毒副作用。
http://
　　【关键词】吉非替尼；艾迪注射液；非小细胞肺癌
　　【中图分类号】R734.2【文献标识码】A【文章编号】1008-6455（2011）10-0037-01【Abstract】Objective:This study evaluated the efficacy and toxicity of Gefitnib combination with aidi injection in treatment of advanced non-smal1-cell lung cancer.Methods:44 patients with advanced non-smal1-cell lung cancer were randomly divided into two groups.The treatment group 22 cases and the control group 22 cases.The treatment group(n=22) was treated with gefitnib and aidi injection. Gefitinib was orally administered 250mg/d and aidi injection iv 50ml/d. The control group(n=22) was treated with gefitnib 250mg/d alone. Results:Response rate and toxicity were assessed in all the 44 patients. The response rate was 40.9% in the treatment group and 27.3% in the control group respectively.The disease control rate was 86.4% for the treatment group and 59.1% for the control group. The disease control rate in the two groups showed statistically significant difference(P参考文献
　　[1]孙燕,石远凯.临床肿瘤内科手册[M] .第五版.北京：人民卫生出版社,2007:880